Nucleome Therapeutics

Nucleome was founded in 2019. The precision of its 3D genomics technology has the potential to improve drug discovery success rates both by discovering genetically-validated medicines, and by more accurately identifying patients who are likely to benefit from treatments. Nucleome’s platform can be applied to multiple disease indications and cell types, with an initial focus on inflammatory conditions. In addition to building its own pipeline, the company is forging external collaborations in target discovery, target validation, and patient stratification. Nucleome was founded by leading experts in gene regulation from the University of Oxford. The Company is backed by a world-class syndicate of investors that includes M Ventures, the strategic corporate venture capital arm of Merck KGaA; Johnson and Johnson Innovation-JJDC, Inc.(“JJDC”), the strategic venture capital arm of Johnson & Johnson; Pfizer Ventures, the venture group of Pfizer; British Patient Capital; and founding investor Oxford Science Enterprises.